Drug Trial Radar · NCT06079281
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
124
Actual
Start
Jan 3, 2024
Primary completion
Jul 9, 2025
Study completion Mar 29, 2028
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.
Conditions
- Hypophosphatasia
Interventions
ALXN1850Drug
ALXN1850 will be administered via subcutaneous (SC) injection.
PlaceboDrug
Placebo will be administered via SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in 6-Minute Walk Test (6MWT) at the end of the Randomized Evaluation Period (Day 169)Time frame: Baseline, Day 169
Locations
65 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Indianapolis, Indiana
Research Site
Garden City, New York
Research Site
Durham, North Carolina
Research Site
Columbus, Ohio
Research Site
Nashville, Tennessee
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Clayton, Australia
Research Site
Herston, Australia
Research Site
Parkville, Australia
Research Site
St Leonards, Australia
Research Site
Belo Horizonte, Brazil
Research Site
Brasília, Brazil
Research Site
Recife, Brazil
Research Site
Salvador, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Winnepeg, Manitoba, Canada
Research Site
Oakville, Ontario, Canada
Research Site
Trois-Rivières, Quebec, Canada
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Nanchang, China
Research Site
Qingdao, China
Research Site
Shanghai, China
Research Site
Shenzhen, China
Research Site
Paris, France
Research Site
Poitiers, France
Research Site
Bad Reichenhall, Germany
Research Site
Berlin, Germany
Research Site
Bonn, Germany
Research Site
Hamburg, Germany
Research Site
Würzburg, Germany
Research Site
Ashkelon, Israel
Research Site
Ramat Gan, Israel
Research Site
Florence, Italy
Research Site
Milan, Italy
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.